Opus Genetics has dosed the first subject in its Phase I/II clinical trial of OPGx-Best1 gene therapy for the treatment of Best disease (BEST1). Best disease, also known as vitelliform macular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results